about
The MTA at 8 Years: Prospective Follow-up of Children Treated for Combined-Type ADHD in a Multisite Study3-Year Follow-up of the NIMH MTA StudyPublic knowledge, beliefs, and treatment preferences concerning attention-deficit hyperactivity disorderCost-effectiveness of ADHD treatments: findings from the multimodal treatment study of children with ADHDA clinical review of outcomes of the multimodal treatment study of children with attention-deficit/hyperactivity disorder (MTA).Blood pressure and heart rate over 10 years in the multimodal treatment study of children with ADHD.Adjunctive divalproex versus placebo for children with ADHD and aggression refractory to stimulant monotherapy.Efficacy and effectiveness of child and adolescent psychotherapy and pharmacotherapy.Stimulant-responsive and stimulant-refractory aggressive behavior among children with ADHDThe Development and Evaluation of a Parent Empowerment Program for Family Peer AdvocatesPharmacotherapies for attention-deficit/hyperactivity disorder: expected-cost analysis.The Texas Children's Medication Algorithm Project: revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder.Developmental processes in peer problems of children with attention-deficit/hyperactivity disorder in the Multimodal Treatment Study of Children With ADHD: developmental cascades and vicious cycles.Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY). Part I: a review.Developing strategies for psychopharmacological studies in preschool children.Comorbidity and child psychopathology: recommendations for the next decade.Mental health assessments in juvenile justice: report on the consensus conference.Experts' recommendations for treating maladaptive aggression in youth.A review of the growing evidence base for pediatric psychopharmacology.Treatment for ADHD: is more complex treatment cost-effective for more complex cases?Parent perspectives on the decision to initiate medication treatment of attention-deficit/hyperactivity disorder.What is the evidence for evidence-based treatments? A hard look at our soft underbelly.Unanswered questions regarding atypical antipsychotic use in aggressive children and adolescents.Association of brain-derived neurotrophic factor (BDNF) Val66Met polymorphism with early-onset bipolar disorder.Improving recognition of adolescent depression in primary care.Interventions for adolescent depression in primary care.Remission versus response as the goal of therapy in ADHD: a new standard for the field?Consensus report on impulsive aggression as a symptom across diagnostic categories in child psychiatry: implications for medication studies.Antidepressant medications and other treatments of depressive disorders: a CINP Task Force report based on a review of evidence.Diffusion of efficacious interventions for children and adolescents with mental health problems.Evidence, interpretation, and qualification from multiple reports of long-term outcomes in the Multimodal Treatment study of Children With ADHD (MTA): part I: executive summary.Evidence, interpretation, and qualification from multiple reports of long-term outcomes in the Multimodal Treatment Study of children with ADHD (MTA): Part II: supporting details.Review: methylphenidate and psychosocial treatments either alone or in combination reduce ADHD symptoms.Changes in emotions related to medication used to treat ADHD. Part II: clinical approaches.Changes in emotions related to medication used to treat ADHD. Part I: literature review.Treatment of maladaptive aggression in youth: CERT guidelines I. Engagement, assessment, and management.Children's response to parental separation during operation desert storm.Who is at greatest risk of adverse long-term outcomes? The Finnish From a Boy to a Man study.Risk, protective factors, and supportive interventions in chronic airway obstruction.Cost assessment of a school-based mental health screening and treatment program in New York City.
P50
Q22242740-70FAAC26-436F-4451-A271-2781DB6F196CQ22242744-A6716393-2D78-479C-BA5C-C6B01F3F9953Q24647537-FA14316A-C7AB-4924-B23B-69AC7AA412B8Q28269957-82DD3555-7DEB-43A6-A306-F98201CC688BQ33925017-DA089B29-F808-4C82-8B35-4E569610B81BQ34045097-F1C38866-1DB4-4CF3-AB63-B41F5568DDAFQ34131298-5E9C0FB5-63F6-40AF-A5AC-69A008E58DF9Q34189982-739879FF-F98D-4CF6-8FC3-A593E2B83718Q34205490-1913B435-C745-487E-A7B5-EDFB6FEF40EFQ34469950-D823D2A1-8124-4DFB-8EFB-0562491A3F86Q34479150-2CDDCF23-0A6D-400C-9C1C-2E4EC9A6B0BBQ34529904-0EC2CD78-3FFA-4F31-AECB-A8BC962928B0Q34680939-FAFB281D-8702-4847-9E75-42CC6FF6CEC4Q35051679-BDBF3116-9EA2-4D14-A5DB-1707B659AA7CQ35089709-F15448C9-8B72-4BAF-B9E8-EA601174163AQ35140174-4327A566-1D64-4C15-86D6-0F864EA60B6BQ35159449-A9266F0E-9870-473D-B6AF-DF971CF1684EQ35757728-FC776298-3595-4F4C-80D1-6D736663B7BFQ35893853-B552F82E-8FF0-4436-B780-5A792DB2491EQ35954908-F1690708-797E-4013-A429-570157C939C3Q36029110-947EA122-58C1-4734-AB9E-DD8D2C66737AQ36099277-D897F18E-D7B2-43E0-A43D-AE040BEB52BFQ36135319-E8C1C66E-5A44-4BE3-A54C-80E0D1E459D4Q36353757-EB853688-28DA-4511-B0C2-F93F9AE793E5Q36526668-4B4540DB-12EB-47E2-9B6C-D98F81200327Q36554227-912B35C6-A8E9-4EA4-8C77-F02B876DAD41Q36703214-719F2CB4-C6AD-443C-BAA0-4BB1A2860735Q36741979-A028B067-140A-4E45-B20D-C3A34E3B5F47Q37039104-F3614ACA-0AA9-49D6-920F-D83736CD57BAQ37107519-9C5BDDC7-B164-4073-B484-39EDCBDE6D5AQ37198292-9875E900-62CD-4927-B1DB-6CCFA1BCF422Q37198296-C2DBF6E9-04A8-4C1E-84BD-0ADF19856873Q37379625-210EF731-2634-47F4-9A49-317FFF54A1B7Q37790840-0309CCB5-C17B-40DB-A30C-A87B0E65DE62Q37793743-101DA18D-ED97-442F-A21D-0C0CD777E3F4Q38014043-183B1458-D486-49FC-ACAA-D658EFA4589FQ39104767-7223463f-4ee6-efb9-0f98-0ebbf3f7ecf4Q40181475-143FF9D7-01AB-44A4-B852-D68C73D4A3A2Q40233246-7C0FB244-39EE-405B-8CEC-2B812295CD64Q40477038-8A4E33FC-82E3-4DE8-8A18-25144A836324
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Peter S Jensen
@nl
Peter S Jensen
@sl
Peter S. Jensen
@en
Peter S. Jensen
@es
type
label
Peter S Jensen
@nl
Peter S Jensen
@sl
Peter S. Jensen
@en
Peter S. Jensen
@es
altLabel
Peter S. Jensen
@en
prefLabel
Peter S Jensen
@nl
Peter S Jensen
@sl
Peter S. Jensen
@en
Peter S. Jensen
@es
P106
P1153
36063397300
P2038
Peter_Jensen
P21
P31
P496
0000-0003-2387-0650